Paltusotine + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Syndrome
Conditions
Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
Trial Timeline
Nov 19, 2025 → Jan 1, 2030
NCT ID
NCT07087054About Paltusotine + Placebo
Paltusotine + Placebo is a phase 3 stage product being developed by Crinetics Pharmaceuticals for Carcinoid Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07087054. Target conditions include Carcinoid Syndrome, Carcinoid, Carcinoid Tumor.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07087054 | Phase 3 | Recruiting |
| NCT05192382 | Phase 3 | Active |
| NCT04837040 | Phase 3 | Active |
| NCT03792555 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoid Syndrome